NEW YORK, July 21, 2022 /PRNewswire/ Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical technology, tools and diagnostics, biopharmaceuticals and digital health subsectors. Ally Bridge Group was founded in 2013 by Frank Yu and has offices in New York and Hong Kong. In a recent letter sent to investors, Mr. Yu explained Dr. Simeonidis will partner with him in leading firmwide strategic initiatives and achieving investment objectives. Mr. Yu will remain at the Firm as Founder, Co-Chief
New-york
United-states
Beth-israel-medical-center
Canada
Hong-kong
Simos-simeonidis
Frank-yu
Morgan-stanley
Group-the-firm
Head-of-research
Firm-as-co
Firm-as-founder
NEW YORK, July 21, 2022 /PRNewswire/ Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical technology, tools and diagnostics, biopharmaceuticals and digital health subsectors. Ally Bridge Group was founded in 2013 by Frank Yu and has offices in New York and Hong Kong. In a recent letter sent to investors, Mr. Yu explained Dr. Simeonidis will partner with him in leading firmwide strategic initiatives and achieving investment objectives. Mr. Yu will remain at the Firm as Founder, Co-Chief
New-york
United-states
Beth-israel-medical-center
Canada
Hong-kong
Simos-simeonidis
Frank-yu
Morgan-stanley
Group-the-firm
Head-of-research
Firm-as-co
Firm-as-founder
Share this article
NEW YORK, Feb. 4, 2021 /PRNewswire/
Record quarterly revenue and earnings per share, resulting in significant full year profitability and accelerated debt reduction
Quarterly revenues of $140.7 million, up 32% from prior year fourth quarter
Annual revenues of $311.7 million, up 4% from prior year
Compensation ratio of 33% for the fourth quarter in order to reduce the ratio to 62% for the full year
Operating profit margin of 57% for the fourth quarter, 18% for the full year
Accelerated debt reduction with $20 million discretionary repayment in fourth quarter
Board authorized up to $50 million of purchases of shares and share equivalents
Recruited additional Managing Director to expand our coverage of the Latin American sector
New-york
United-states
Tokyo
Japan
Hong-kong
Paris
France-general
France
Madrid
Spain
Brazil
Melbourne
vimarsana © 2020. All Rights Reserved.